DOAC Antidotes No Panacea for Fatal Bleeds medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Patients with peripheral artery disease and HF have higher rates of CAD and elevated risk for adverse CV events and mortality compared with patients with PAD but no HF, researchers reported.“The presence of PAD has been associated with increased morbidity and mortality in patients with HF,” Marc D. Samsky, MD, cardiologist in the Duke Clinical Research Institute at Duke University
Slone Partners Places Susan Landis as Executive Director at the Association of Clinical Research Professionals’ Board of Trustees
Share Article
New ED brings more than 25 years of experience in organizational leadership
“Susan Landis is an extremely accomplished and respected business leader with a strong expertise in life sciences, technology, and digital health,” said Slone Partners President Tara Kochis-Stach. SOUTH RIDING, Va. (PRWEB) June 02, 2021
Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Susan Landis as Executive Director of the Association of Clinical Research Professionals’(ACRP) Board of Trustees. She will begin serving in her new role effective June 14, 2021.
May 27, 2021
Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff.
That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall healthcare costs in those nations, investigators led by Justin Parizo, MD (Stanford University, CA), say.
“Cost-effectiveness analyses are inherently tied to the society in which they’re evaluated,” senior author Alexander Sandhu, MD (Stanford University), explained to TCTMD. “While the clinical benefits might be quite similar across different contexts and populations, the costs of therapy
Heart Benefits of DASH Low-Sodium Diet Swift and Direct medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.